Shutterstock
Ricoh Company, Ltd. have announced a non-exclusive licensing agreement in the USA and Japan with ERS Genomics Limited for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS Genomics.
CRISPR/Cas9 stands as a breakthrough gene editing technology, enabling modification of targeted genome sequences with ease. The technology is an essential tool in drug discovery research and finds application across various fields.
In 2022, Ricoh completed the acquisition of Elixirgen Scientific, Inc. (Baltimore, Maryland, USA). Elixirgen Scientific possesses core technologies in rapid and efficient differentiation of human iPS cells, and mRNA design, production, and management.
We aim to predict the mechanism of action of candidate drugs for patients with varied genetic backgrounds and to improve the speed and efficiency of mRNA design by combining these core technologies with CRISPR/Cas9 genome editing technology. Through manipulations such as genetic editing of cells to enhance or diminish specific functions, it becomes possible to create highly reliable disease models, including those for rare diseases. This advancement is anticipated to lead to shorter drug development timelines and increased success rates.
Ricoh has been expanding the application areas of Elixirgen Scientific's technology by leveraging our cultivated expertise in digital and artificial intelligence technologies. This initiative aims to accelerate personalised medicine, drug discovery research and regenerative medicine. Ricoh continues to contribute to the acceleration of drug development research through the diverse solutions provided by Elixirgen Scientific.
Summit Pharmaceuticals International Corporation (Chiyoda-ku, Tokyo, Japan), a subsidiary of Sumitomo Corporation (Chiyoda-ku, Tokyo, Japan), is the exclusive representative of ERS Genomics in Japan.